MARKET WIRE NEWS

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Source: SeekingAlpha

2025-03-28 13:39:25 ET

Summary

  • Harrow, Inc. is a speculative buy, with potential trading gains from the $20s to the $30s, and long-term growth prospects.
  • The company reported strong Q4 growth, with an 84% revenue increase and improved gross profit margins, driven by key products IHEEZO and VEVYE.
  • Harrow's 2025 revenue guidance is bullish, expecting over $280 million, a 40% increase, supported by the VEVYE Access for All program.
  • With a compelling valuation and potential EPS growth into 2026, HROW stock is a strong speculative trade, especially with upcoming MELT-300 developments.

Harrow, Inc. ( HROW ) is a name that has once again caught our eye after several months of a selloff. Folks, we pegged this as a speculative trade last summer in the high $30s. The stock ran to the high $50s in a few short weeks, providing massive rapid-returns for those who followed along. However, if you did not sell, and chose to hold, you are in some pain....

Read the full article on Seeking Alpha

For further details see:

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp
Harrow Health Inc. 8.625% senior notes due 2026

NASDAQ: HROWL

HROWL Trading

0.11% G/L:

$25.591 Last:

3,436 Volume:

$25.55 Open:

mwn-app Ad 300

HROWL Latest News

May 23, 2025 02:16:00 am
Long Term Trading Analysis for (HROWL)
February 28, 2025 12:14:00 am
Objective long/short (HROWL) Report
February 17, 2025 09:52:00 am
Where are the Opportunities in (HROWL)

HROWL Stock Data

$947,624,703
31,392,612
N/A
160
6427%
Pharmaceuticals
Healthcare
US
Nashville

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App